Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
Merck and Eisai announced new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Roche company Genentech presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Bristol Myers Squibb announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care compared to conventional care did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.
Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of the company’s checkpoint inhibitor Opdivo (nivolumab).
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival in patients with previously untreated, unresectable malignant pleural mesothelioma in the Phase 3 CheckMate -743 clinical trial.
Helsinn Group, based in Lugano, Switzerland, and MEI Pharma, with headquarters in San Diego, announced they were discontinuing their Phase III trial of pracinostat with azacytidine in acute myeloid leukemia (AML).
Sanofi and Regeneron halted a Phase III study of the checkpoint inhibitor Libtayo (cemiplimab) as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.